Cargando…
The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia
Schizophrenia is a complex and incompletely elucidated pathology that affects sensorimotor function and also produces numerous therapeutic challenges. The aims of this cross-sectional study were to identify the profile of neurological soft signs (NSS) in patients with predominantly negative symptoms...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687986/ https://www.ncbi.nlm.nih.gov/pubmed/36428507 http://dx.doi.org/10.3390/biomedicines10112939 |
_version_ | 1784836152018075648 |
---|---|
author | Petrescu, Cristian Papacocea, Ioana R. Vilciu, Crisanda Mihalache, Oana A. Vlad, Diana M. Marian, Gabriela Focseneanu, Brindusa E. Sima, Cristian T. Ciobanu, Constantin A. Riga, Sorin Ciobanu, Adela M. |
author_facet | Petrescu, Cristian Papacocea, Ioana R. Vilciu, Crisanda Mihalache, Oana A. Vlad, Diana M. Marian, Gabriela Focseneanu, Brindusa E. Sima, Cristian T. Ciobanu, Constantin A. Riga, Sorin Ciobanu, Adela M. |
author_sort | Petrescu, Cristian |
collection | PubMed |
description | Schizophrenia is a complex and incompletely elucidated pathology that affects sensorimotor function and also produces numerous therapeutic challenges. The aims of this cross-sectional study were to identify the profile of neurological soft signs (NSS) in patients with predominantly negative symptoms of schizophrenia (PNS) compared with patients with schizophrenia who do not present a predominance of negative symptoms (NPNS) and also to objectify the impact of treatment on the neurological function of these patients. Ninety-nine (n = 99; 56 females and 43 males) patients diagnosed with schizophrenia according to DSM-V were included; these patients were undergoing antipsychotic (4 typical antipsychotics, 86 atypical antipsychotics, and 9 combinations of two atypical antipsychotics) or anticholinergic treatment (24 out of 99) at the time of evaluation, and the PANSS was used to identify the patients with predominantly negative symptoms (n = 39), the Neurological Evaluation Scale (NES) was used for the evaluation of neurological soft signs (NSS), and the SAS was used for the objectification of the extrapyramidal side effects induced by the neuroleptic treatment, which was converted to chlorpromazine equivalents (CPZE). The study’s main finding was that, although the daily dose of CPZE did not represent a statistically significant variable, in terms of neurological soft signs, patients with PNS had higher rates of NSS. |
format | Online Article Text |
id | pubmed-9687986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96879862022-11-25 The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia Petrescu, Cristian Papacocea, Ioana R. Vilciu, Crisanda Mihalache, Oana A. Vlad, Diana M. Marian, Gabriela Focseneanu, Brindusa E. Sima, Cristian T. Ciobanu, Constantin A. Riga, Sorin Ciobanu, Adela M. Biomedicines Article Schizophrenia is a complex and incompletely elucidated pathology that affects sensorimotor function and also produces numerous therapeutic challenges. The aims of this cross-sectional study were to identify the profile of neurological soft signs (NSS) in patients with predominantly negative symptoms of schizophrenia (PNS) compared with patients with schizophrenia who do not present a predominance of negative symptoms (NPNS) and also to objectify the impact of treatment on the neurological function of these patients. Ninety-nine (n = 99; 56 females and 43 males) patients diagnosed with schizophrenia according to DSM-V were included; these patients were undergoing antipsychotic (4 typical antipsychotics, 86 atypical antipsychotics, and 9 combinations of two atypical antipsychotics) or anticholinergic treatment (24 out of 99) at the time of evaluation, and the PANSS was used to identify the patients with predominantly negative symptoms (n = 39), the Neurological Evaluation Scale (NES) was used for the evaluation of neurological soft signs (NSS), and the SAS was used for the objectification of the extrapyramidal side effects induced by the neuroleptic treatment, which was converted to chlorpromazine equivalents (CPZE). The study’s main finding was that, although the daily dose of CPZE did not represent a statistically significant variable, in terms of neurological soft signs, patients with PNS had higher rates of NSS. MDPI 2022-11-15 /pmc/articles/PMC9687986/ /pubmed/36428507 http://dx.doi.org/10.3390/biomedicines10112939 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Petrescu, Cristian Papacocea, Ioana R. Vilciu, Crisanda Mihalache, Oana A. Vlad, Diana M. Marian, Gabriela Focseneanu, Brindusa E. Sima, Cristian T. Ciobanu, Constantin A. Riga, Sorin Ciobanu, Adela M. The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title | The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title_full | The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title_fullStr | The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title_full_unstemmed | The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title_short | The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia |
title_sort | impact of antipsychotic treatment on neurological soft signs in patients with predominantly negative symptoms of schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687986/ https://www.ncbi.nlm.nih.gov/pubmed/36428507 http://dx.doi.org/10.3390/biomedicines10112939 |
work_keys_str_mv | AT petrescucristian theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT papacoceaioanar theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT vilciucrisanda theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT mihalacheoanaa theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT vladdianam theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT mariangabriela theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT focseneanubrindusae theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT simacristiant theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT ciobanuconstantina theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT rigasorin theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT ciobanuadelam theimpactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT petrescucristian impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT papacoceaioanar impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT vilciucrisanda impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT mihalacheoanaa impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT vladdianam impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT mariangabriela impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT focseneanubrindusae impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT simacristiant impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT ciobanuconstantina impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT rigasorin impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia AT ciobanuadelam impactofantipsychotictreatmentonneurologicalsoftsignsinpatientswithpredominantlynegativesymptomsofschizophrenia |